Study guide

Vascular Access, Infusion Monitoring, and Extravasation Prevention

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Vascular Access, Infusion Monitoring, and Extravasation Prevention

Key Takeaways Explain This Topic AI

Vesicants (anthracyclines, vinca alkaloids) require central access or a fresh, well-monitored peripheral site; verify patency and blood return per policy.

Avoid the antecubital fossa, wrist, and areas of flexion for vesicant peripheral infusion because dislodgement and monitoring difficulty raise extravasation risk.

Suspected extravasation: stop the infusion, do NOT flush or remove the catheter, aspirate residual drug, and follow the drug-specific antidote and compress protocol.

Anthracyclines use cold compresses and dexrazoxane; vinca alkaloids and vinblastine use warm compresses and hyaluronidase.

Central-line fever during neutropenia and new arm or neck swelling signal possible CLABSI or thrombosis and require urgent escalation.

Last updated: June 2026

Vascular Access, Infusion Monitoring, and Extravasation Prevention

Systemic therapy depends on safe vascular access. Device choice reduces delays, tissue injury, infection, and thrombosis. Selection weighs vesicant status, osmolarity, pH, infusion duration, vein quality, lymphedema risk, and patient preference. A vesicant causes tissue necrosis if it leaks; an irritant causes inflammation or pain without necrosis; a nonvesicant does neither.

Vesicant Examples and Access

Known DNA-binding vesicants include the anthracyclines (doxorubicin, daunorubicin) and non-DNA-binding vesicants include the vinca alkaloids (vincristine, vinblastine). Vesicants are preferentially given through central venous access (implanted port, tunneled catheter, or peripherally inserted central catheter [PICC]); when a peripheral route is used, choose a fresh, large forearm vein with the site visible, confirm blood return, and avoid the antecubital fossa, wrist, hand, and any area of flexion.

  • Access issue Nursing action
  • No blood return when required Stop and troubleshoot per policy before administering
  • Pain or burning Pause and assess for infiltration or extravasation
  • Swelling or coolness Stop infusion and evaluate site immediately
  • Redness or drainage Assess for phlebitis or infection; notify provider
  • Resistance on flushing Do not force; follow occlusion protocol
  • Suspected Extravasation Response

Extravasation is leakage of a vesicant into surrounding tissue. If suspected: stop the infusion immediately, leave the catheter in place, aspirate residual drug through the catheter, do not flush, and disconnect tubing. Then apply the drug-specific antidote and compress:

Anthracyclines (e.g., doxorubicin): apply cold compresses to localize; give dexrazoxane IV in a different limb if ordered (within about 6 hours).

Vinca alkaloids (e.g., vincristine, vinblastine): apply warm compresses to disperse; give hyaluronidase subcutaneously around the site.

Mark and photograph the area per policy, measure it, notify provider and pharmacy, document thoroughly, and arrange follow-up because tissue injury evolves over days. Applying the wrong temperature (cold to a vinca alkaloid, warm to an anthracycline) worsens injury.

Infusion Monitoring and Central-Line Complications

Monitor vital signs, line patency, pump settings, and symptoms, with heightened reaction readiness for first infusions, taxanes, platinums, monoclonal antibodies, and asparaginase. Emergency equipment must be available. For central lines, assess dressing integrity, blood return, and patient-reported changes. Fever with a central line during neutropenia demands prompt evaluation for central-line-associated bloodstream infection (CLABSI). New arm, neck, or facial swelling on the catheter side suggests catheter-related thrombosis. Teach patients to keep dressings dry, avoid pulling the line, and report fever or drainage.

Device Selection in Practice

The right device prevents downstream harm. Peripheral IV access suits short, nonvesicant, low-osmolarity infusions in a healthy, visible vein. Central access is preferred or required for vesicants, continuous infusions, poor peripheral veins, frequent draws, prolonged therapy, or vesicant chemotherapy. Each central device carries a distinct risk profile: implanted ports lower infection and body-image burden but require needle access through skin; tunneled catheters and PICCs offer immediate access but add daily maintenance and thrombosis risk.

The RN matches device to therapy and escalates when the planned drug does not fit the available access rather than forcing a vesicant through a marginal peripheral site.

Why Compress Direction Matters

The cold-versus-warm rule is a frequently tested distinction. For DNA-binding anthracycline vesicants, cold vasoconstricts and localizes the drug, limiting the area of necrosis, and dexrazoxane neutralizes the tissue injury. For non-DNA-binding vinca alkaloids, warm vasodilates and disperses the drug to dilute it, and hyaluronidase breaks down tissue barriers to spread and absorb the small leaked volume. Reversing these (warming an anthracycline or cooling a vinca alkaloid) worsens the lesion, so the nurse always consults the agent-specific protocol rather than applying a single generic response.

Injury can evolve over days to weeks, so photographic documentation, measurement, and scheduled follow-up are part of the standard.

A Common Safety Failure

A frequent error is assuming a quiet patient has no site symptoms. Many patients minimize discomfort because they traveled far or fear a delay. The RN should invite reporting in direct language, pain, burning, tightness, pressure, or wetness should be reported immediately, and should recheck the site after position changes, bathroom trips, and pump alarms. Early interruption of an infusion through uncertain access is always safer than finishing the dose and discovering necrosis later.

Distinguishing Infiltration, Extravasation, and Flare

Three look-alike events require different responses. Infiltration is leakage of a nonvesicant into tissue, causing swelling and coolness but not necrosis; the nurse stops, removes the catheter, and elevates. Extravasation is leakage of a vesicant and threatens tissue loss, demanding the stop-aspirate-antidote sequence with the catheter left in place.

A flare reaction (most classic with doxorubicin) is a transient local erythema, urticaria, or streaking along the vein, with blood return still intact and no pain or swelling; it is a local hypersensitivity, not extravasation, and usually resolves, though the nurse pauses and assesses to confirm patency before resuming. Mistaking a flare for extravasation triggers unnecessary intervention, while mistaking extravasation for a flare delays the antidote, so the distinguishing features, pain, swelling, and loss of blood return, must be assessed deliberately.

Monitoring High-Risk First Infusions

Reaction readiness scales with the agent. First infusions of monoclonal antibodies, taxanes, platinum agents, and asparaginase products carry elevated reaction risk, so the nurse confirms emergency medications and equipment are at hand, takes baseline vital signs, and stays at the bedside through the early minutes. The RN must be able to pause the infusion, maintain access with non-drug fluid, call for help, and support airway and circulation while awaiting provider direction, the same reflex used for any infusion reaction.